Literature DB >> 25689636

Perspectives on the increased risk of second cancer in patients with essential thrombocythemia, polycythemia vera and myelofibrosis.

Hans Carl Hasselbalch1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25689636     DOI： 10.1111/ejh.12437

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN： 0902-4441            Impact factor:   2.997


× No keyword cloud information.
  8 in total

1.  Patients with myeloproliferative neoplasms and high levels of systemic inflammation develop age-related macular degeneration.

Authors:  Charlotte Liisborg; Marie Krogh Nielsen; Hans Carl Hasselbalch; Torben Lykke Sørensen
Journal:  EClinicalMedicine       Date:  2020-09-09

2.  Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia.

Authors:  Cristina Santoro; Isabella Sperduti; Roberto Latagliata; Erminia Baldacci; Barbara Anaclerico; Giuseppe Avvisati; Massimo Breccia; Francesco Buccisano; Michele Cedrone; Giuseppe Cimino; Cinzia De Gregoris; Marianna De Muro; Ambra Di Veroli; Sabrina Leonetti Crescenzi; Marco Montanaro; Enrico Montefusco; Raffaele Porrini; Angela Rago; Antonio Spadea; Francesca Spirito; Nicoletta Villivà; Alesssandro Andriani; Giuliana Alimena; Maria Gabriella Mazzucconi
Journal:  Cancer Med       Date:  2017-05-23       Impact factor: 4.452

3.  Transcriptome reveals the overexpression of a kallikrein gene cluster (KLK1/3/7/8/12) in the Tibetans with high altitude-associated polycythemia.

Authors:  Kang Li; Luobu Gesang; Zeng Dan; Lamu Gusang
Journal:  Int J Mol Med       Date:  2016-12-14       Impact factor: 4.101

4.  Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges.

Authors:  Karan Seegobin; Bharatsinh Gharia; Satish Maharaj; Lara Zuberi
Journal:  Case Rep Hematol       Date:  2018-08-12

5.  IRF4 and IRF8 expression are associated with clinical phenotype and clinico-hematological response to hydroxyurea in essential thrombocythemia.

Authors:  Xiao Huang; Tingting Ma; Yongmei Zhu; Bo Jiao; Shanhe Yu; Kankan Wang; Jian-Qing Mi; Ruibao Ren
Journal:  Front Med       Date:  2021-07-31       Impact factor: 9.927

Review 6.  MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives.

Authors:  Hans Carl Hasselbalch; Mads Emil Bjørn
Journal:  Mediators Inflamm       Date:  2015-10-28       Impact factor: 4.711

Review 7.  Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses.

Authors:  Vibe Skov
Journal:  Cancers (Basel)       Date:  2020-08-06       Impact factor: 6.639

Review 8.  Second Cancer Onset in Myeloproliferative Neoplasms: What, When, Why?

Authors:  Cosimo Cumbo; Luisa Anelli; Antonella Zagaria; Nicoletta Coccaro; Francesco Tarantini; Giorgina Specchia; Pellegrino Musto; Francesco Albano
Journal:  Int J Mol Sci       Date:  2022-03-15       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.